Infrainguinal occlusive disease: endovascular intervention is the first line therapy.
The preferred treatment of infrainguinal occlusive disease at many centers has undergone a paradigm shift from open bypass to endovascular intervention as the first-line therapeutic modality. Our own experience supports a percutaneous first approach. Though skeptics initially cited lower primary patency rates for angioplasty when compared with bypass, more recent studies have shown favorable secondary patencies nearly challenging that of bypass. The need for repeat endovascular intervention to achieve a higher secondary patency is not a major deterring factor because most procedures are associated with a short hospital stay and a relatively low rate of complication. The risk is low and this complex group of patients can tolerate minimally invasive reinterventions well. The longevity of this patient population is generally short, and consequently less durable outcomes may be acceptable. Patients do require close follow-up with early treatment of restenosis. However, there appears to be a decreased cost of intervention when compared with surgery. Furthermore, the functional outcomes and quality of life appear more optimal with angioplasty. The concern that angioplasty may preclude future surgical intervention by damaging the distal bypass target has not borne true. It is unusual for a percutaneous therapy to eliminate the possibility of a bypass should the endovascular approach not be successful. Finally, advances in techniques and devices may herald improved outcomes because percutaneous therapy in the periphery is still in the early stages of its maturation. Thus, endovascular intervention has become an established, as well as a developed method for treating peripheral arterial occlusive disease and should be considered the first-line therapeutic modality for patients with.lower extremity vascular disease.